Financing
PepGen launches $125 million stock offering to fund clinical programs
PepGen, which develops oligonucleotide therapies for rare genetic diseases, proposed selling $125 million of shares, with pre-funded warrants for some investors. Underwriters would get a 30-day option on another $18.75 million. Proceeds are earmarked for clinical development and general corporate needs.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.